Fennec Pharmaceuticals Posts 50% Revenue Growth on PEDMARK Adoption
Event summary
- Fennec Pharmaceuticals reported $44.6M in full-year 2025 net product sales, up 50% YoY, with Q4 sales hitting $13.8M (75% QoQ growth).
- Completed $42M equity offerings with new and existing investors, eliminating all debt by year-end 2025.
- Expanded clinical evidence for PEDMARK® in new tumor types and patient populations through investigator-initiated studies.
- Announced positive topline results from Japanese Phase 2/3 trial (STS-J01) for cisplatin-induced ototoxicity prevention.
The big picture
Fennec's 50% revenue growth reflects accelerating adoption of PEDMARK® in cisplatin-based chemotherapy, particularly among adolescent and young adult (AYA) cancer patients. The company's strategic pivot toward real-world evidence generation and expanded field team positions it to capture a larger share of the $500M U.S. market for ototoxicity prevention. The $42M equity raise and debt elimination strengthen its balance sheet for potential partnerships or licensing opportunities abroad.
What we're watching
- Commercial Expansion
- Whether Fennec can sustain its 75% QoQ growth in Q1 2026 following its field team expansion.
- Regulatory Progress
- The pace at which Fennec advances PEDMARK® registration in Japan following positive STS-J01 results.
- Clinical Validation
- How new real-world data from head and neck cancer patients impacts PEDMARK® adoption in adult populations.
Related topics